Article Correctness Is Author's Responsibility: Galcanezumab Effective at Decreasing Monthly Headache Days in Migraine

The article below may contain offensive and/or incorrect content.

Approximately 40% of patients with episodic migraine who were treated with galcanezumab achieved 100% response rate for at least 1 month.